My summary of CARTITUDE4, MajesTEC3, MajesTEC9 and MoumenTAL3. In anti-CD38 refractory patients and EMDs -->TCE anti-BCMA or anti-GPRC5D are >> to Cilta-Cel

Arlo-cel (anti-GPRC5D CAR T-cell) in Rel/ref MM. N=84, 5 prior lines of Rx, 49% anti-BCMA-exposed. CRS: 82%, ICANS 10%, other NT: 12%. Skin/nail AE: 30/19%, oral AE: 32%. ORR 87%, median PFS: 18.3 months #mmsm #bmtsm @SusanBal9 @BloodPortfolio ashpublications.org/blood/ar…

One of the most rewarding and emotional moments of my career took place at #ASCO2026. In 2015, I started the first-in-human trial of 11-1F4 (now anselamimab), supported by a small FDA grant and @columbiacancer. At the time, the path forward was far from certain. We faced limited funding, strong competition from Prothena’s NEOD001 program, and considerable skepticism from industry given the rarity of AL amyloidosis and the fact that competing programs were already much further advanced in development. Despite these challenges, we continued to move forward step by step. The phase 1 study demonstrated encouraging results, ultimately leading to the founding and funding of Caelum Biosciences in 2017 and the launch of the subsequent phase 2 and phase 3 studies. Those efforts were later advanced and completed through the commitment and resources of @AlexionCARES and @AstraZenecaUS. @ASCO I had the privilege of chairing the session when the final phase 3 results where presented by Dr. Wechalekar, which demonstrated a significant overall survival benefit in patients with stage IIIA/IIIB κ AL amyloidosis🙌. Seeing a scientific concept evolve from an investigator-initiated first-in-human study into a positive phase 3 trial is extraordinarily rewarding. This achievement reflects the dedication of countless patients, supporters🙏@MorieGertz, investigators, research staff, industry partners, and advocates who believed in this program over many years. It is also a powerful reminder of why we do translational research-to transform promising science into therapies that meaningfully improve patients' lives. #ASCO2026 #ALAmyloidosis @Amyloidosis_ARC @Amyloidosisfdn @AmyloidosisSupp @ISA_Amyloidosis

Good commentary from @IrenemGhobrial on the complicated question of whether clonotypic B cells are clinically relevant in #mmsm. New Insights into the Role of Clonotypic B Cells in Plasma-cell Neoplasia aacrjournals-org.proxy.libra…

#mmsm #ASCO26 MajesTEC-9 ➡️Tec vs. PVd/Kd (1-3 prior lines of therapy) ➡️Len refractory: 80%; anti-CD38 refractory: 85% ➡️median F/U ~1.5 yrs ➡️18-mo PFS rate: 70% vs 27% ➡️improved OS with Tec vs PVd/Kd (HR: 0.60), even with >2/3 of pts getting BsAb or CAR-T as subsequent treatment 🛑Gr 5 TEAEs (6.5% vs 3.5%)-higher with Tec vs PVd/Kd 🛑Gr 3/4 infections were higher with Tec vs PVd/Kd (42% vs 29%) Teclistamab single agent in anti-CD38 refractory is a great option to have in early relapsed myeloma asco.org/abstracts-presentat…

Excellent summary of CAR-PRISM by @HadidiSamer: “For an asymptomatic condition with a risk to progress to a condition that has excellent treatment options and outcomes (and despite the deep responses) those toxicities reported are really concerning”!

Fascinating - albeit a little terrifying - @LeukemiaJnl work by 🇩🇪 How does GPRC5D loss affect surviving myeloma #MMsm clones? Here, remaining cells appear to be more aggressive. Will be important to validate / rebut as talquetamab moves into earlier lines... hopefully soon!

Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome @ImmunityCP cell.com/immunity/fulltext/S… @CharlesSwanton @TheCrick @RobertVendramin @ucl @kevlitchfield @squezadd

Excited to share our new medRxiv preprint on oncology data visualization with R. This collaborative atlas includes 62 reproducible templates for clinical trials and real-world evidence, with simulation-based examples throughout. @drjgauthier @YeinJ_StatML medrxiv.org/content/10.64898…

Congratulations @MattReesMD! More evidence to support the use of CAR-T in appropriately selected patients with MM/AL

Congratulations to Robert Vonderheide, MD, DPhil, director of @PennCancer's Abramson Cancer Center, who has been elected to become the 2026-2027 President-Elect of @AACR. spr.ly/6019B6rtMT

CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation ashpublications.org/blood/ar…

He was not always so rigorous, Venk. cancerletter.com/the-cancer-… forbes.com/sites/matthewherp…

We are honored to have this support from Blood Cancer United and the Riney Foundation, which supports our LimiTec trial of fixed-duration bispecific antibody therapy for multiple myeloma #mmsm.

Outcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma ashpublications.org/bloodadv… Congrats and thanks to our superstar resident Heta Patel for leading this analysis!

Colchicine reduces competitive advantage of clonal hematopoiesis (esp TET2) in COLCOT ahajournals.org/doi/abs/10.1… @CircAHA Similar to LoDoCo2 jacc.org/doi/10.1016/j.jacc.… @JACCJournals Our prior work in mice & human biobanks suggests that colchicine may be effective in reducing TET2 CHIP-associated CVD risk academic.oup.com/eurheartj/a… @ESC_Journals